Grace Therapeutics (GRCE): Opaleye reports 2.75M-share, 13.07% ownership stake

Rhea-AI Filing Summary

Opaleye Management Inc., Opaleye, L.P., and James Silverman report beneficial ownership of Grace Therapeutics, Inc. common stock on a Schedule 13G. The Fund directly holds 2,748,392 shares of common stock, and the Adviser and Mr. Silverman may be deemed to beneficially own these shares through their roles with the Fund.

This position represents 13.07% of the outstanding common stock, based on 21,035,930 shares outstanding as of August 5, 2026, which includes shares issued in an August 4, 2026 private placement in which Opaleye, L.P. participated. Voting and dispositive power over the 2,748,392 shares is reported as shared, with no sole voting or dispositive power.

Key Figures

Shares beneficially owned: 2,748,392 shares Percent of class: 13.07% Shares outstanding baseline: 21,035,930 shares +4 more

7 metrics

Shares beneficially owned 2,748,392 shares Common Stock of Grace Therapeutics, Inc. held by Opaleye, L.P.

Percent of class 13.07% Portion of Grace Therapeutics common stock beneficially owned by reporting persons

Shares outstanding baseline 21,035,930 shares Grace Therapeutics common stock outstanding as of August 5, 2026

Prior outstanding shares 16,274,026 shares Common stock outstanding as of July 28, 2026 per proxy statement

Private placement issuance 4,761,904 shares Shares issued August 4, 2026 in private placement in which Opaleye, L.P. participated

Shared voting power 2,748,392 shares Shares with shared power to vote or direct the vote

Shared dispositive power 2,748,392 shares Shares with shared power to dispose or direct the disposition

Key Terms

beneficially own, shared voting power, shared dispositive power, Schedule 13G, +1 more

5 terms

beneficially own financial

"may be deemed to beneficially own the 2,748,392 shares of Common Stock held directly"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

shared voting power financial

"Shared Voting Power 2,748,392.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

shared dispositive power financial

"Shared Dispositive Power 2,748,392.00"

Schedule 13G regulatory

"This statement is filed by (i) Opaleye Management Inc. ... on a Schedule 13G"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

investment adviser financial

"The Adviser, as investment adviser to the Fund"

An investment adviser is a person or firm that professionally manages money and gives recommendations about buying, selling, or holding investments. Like a financial coach or guide, they have a legal duty to act in a client's best financial interest, so their advice, fees and potential conflicts can directly affect returns and risk — making their role important for investors who want informed, accountable help with portfolios.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/07/2026 - 04:06 PM Accepted by SEC EDGAR 08/07/2026 - 04:05 PM Learn about SEC filing dates

FAQ

How many Grace Therapeutics (GRCE) shares are beneficially owned by the Opaleye reporting group?

The Opaleye reporting group reports beneficial ownership of 2,748,392 shares of Grace Therapeutics common stock. These shares are held directly by Opaleye, L.P., with Opaleye Management Inc. and James Silverman deemed beneficial owners through their advisory and control roles.

What percentage of Grace Therapeutics (GRCE) does Opaleye’s 13G filing represent?

The filing reports that the group beneficially owns 13.07% of Grace Therapeutics’ common stock. This percentage is calculated based on 21,035,930 shares outstanding as of August 5, 2026, including shares issued in an August 4, 2026 private placement.

How were the outstanding shares of Grace Therapeutics (GRCE) calculated in this 13G?

Outstanding shares are stated as 21,035,930, consisting of 16,274,026 shares outstanding as of July 28, 2026 plus 4,761,904 shares issued in an August 4, 2026 private placement. Opaleye, L.P. participated in that private placement.

What voting and dispositive powers over Grace Therapeutics (GRCE) shares are reported by Opaleye?

The reporting persons disclose 0 shares with sole voting or dispositive power and 2,748,392 shares with shared voting and shared dispositive power. This means all reported authority over the position is shared among the reporting persons.

Who are the reporting persons in the Grace Therapeutics (GRCE) Schedule 13G?

The Schedule 13G is filed jointly by Opaleye Management Inc. (the Adviser), Opaleye, L.P. (the Fund), and James Silverman. The Fund directly holds the shares, and the Adviser and Mr. Silverman may be deemed beneficial owners through their respective roles.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Grace Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

00439U104

(CUSIP Number)

08/05/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 00439U104

1

Names of Reporting Persons

Opaleye Management Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MASSACHUSETTS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,748,392.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,748,392.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,748,392.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

13.07 %

12

Type of Reporting Person (See Instructions)

IA, CO

SCHEDULE 13G

CUSIP Number(s): 00439U104

1

Names of Reporting Persons

Opaleye, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,748,392.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,748,392.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,748,392.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

13.07 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: Based on 21,035,930 shares of Common Stock outstanding as of August 5, 2026, consisting of (i) 16,274,026 shares of Common Stock outstanding as of July 28, 2026, as reported by Grace Therapeutics, Inc. in its 2026 proxy statement, and (ii) 4,761,904 shares of Common Stock issued by Grace Therapeutics, Inc. in a private placement on August 4, 2026, in which Opaleye, L.P. participated.

SCHEDULE 13G

CUSIP Number(s): 00439U104

1

Names of Reporting Persons

James Silverman

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,748,392.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,748,392.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,748,392.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

13.07 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Grace Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 103 CARNEGIE CENTER SUITE 300 PRINCETON, NEW JERSEY, 08540
Item 2.
(a)	Name of person filing: This statement is filed by (i) Opaleye Management Inc. (the "Adviser"), (ii) Opaleye, L.P. (the "Fund"), and (iii) James Silverman (collectively, the "Reporting Persons"). The Fund directly holds 2,748,392 shares of Common Stock, par value $0.0001 per share (the "Common Stock"), of Grace Therapeutics, Inc. (the "Issuer"). The Adviser, as investment adviser to the Fund, and Mr. Silverman, as the controlling person of the Adviser, may be deemed to beneficially own the 2,748,392 shares of Common Stock held directly by the Fund. The filing of this statement shall not be construed as an admission that any Reporting Person is the beneficial owner of any securities covered by this statement for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or otherwise.
(b)	Address or principal business office or, if none, residence: One Boston Place, 26th Floor, Boston, MA 02108
(c)	Citizenship: Opaleye Management Inc. - Massachusetts Opaleye, L.P. - Delaware James Silverman - United States
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP Number(s): 00439U104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 2,748,392.00
(b)	Percent of class: 13.07 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 2,748,392.00
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 2,748,392.00
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Opaleye Management Inc.

Signature:	/s/ James Silverman
Name/Title:	President
Date:	08/07/2026

Opaleye, L.P.

Signature:	/s/ James Silverman
Name/Title:	General Partner
Date:	08/07/2026

James Silverman

Signature:	/s/ James Silverman
Name/Title:	Individually
Date:	08/07/2026

Exhibit Information

Exhibit 99.1 Joint Filing Agreement by and among the reporting persons